Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from 22nd Century Group

Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Month

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 3 Risk Off Stocks That Could Blast Off This Month

Top 3 Risk Off Stocks That Could Blast Off This Month

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

22nd Century Group Q3 Revenue Grows 148% YoY, Here Are The Details

22nd Century Group Q3 Revenue Grows 148% YoY, Here Are The Details

22nd Century Group, Inc. (NASDAQ: XXII) net revenues for the third quarter of 2022 were $19.4 million, an increase of 148.2% from 2021.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022

Cannabis Stock Gainers And Losers From June 23, 2022

GAINERS: 22nd Century Group (NASDAQ:XXII) shares closed up 31.12% at $2.57

Cannabis Stock Gainers And Losers From June 22, 2022

GAINERS: 22nd Century Group (NASDAQ:XXII) shares closed up 20.25% at $1.96

Cannabis Movers & Shakers: 22nd Century Group, Houseplant, Proven Media

22nd Century Group Names New CFO 22nd Century Group (NASDAQ: XXII) has appointed f R. Hugh Kinsman to oversee its financial department. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022.

inkl

Read news from The Economist, FT, and more,
with one subscription

22nd Century Group's Return On Capital Employed Insights

22nd Century Group's Return On Capital Employed Insights

According to Benzinga Pro data, during Q1, 22nd Century Group (AMEX:XXII) posted sales of $9.04 million. Earnings were up 36.14%, but 22nd Century Group still reported an overall loss of $8.92 million.

Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International

Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International

Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department.

22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows

22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET.

22nd Century Group: Q1 Earnings Insights

22nd Century Group: Q1 Earnings Insights

22nd Century Group (NASDAQ:XXII) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

New type of cigarette that ‘helps you smoke less’ debuts in Chicago stores this week, amid some controversy

Cigarettes that recently gained authorization from the Food and Drug Administration to be marketed as products that can help smokers cut back are hitting Chicago-area stores this week — the first place in the country where they will be sold.

Chicago Tribune

FDA-Authorized Reduced-Nicotine Cigarette From 22nd Century Group That 'Helps You Smoke Less' To Reach Illinois

FDA-Authorized Reduced-Nicotine Cigarette From 22nd Century Group That 'Helps You Smoke Less' To Reach Illinois

22nd Century Group, Inc. (NASDAQ:XXII) received notification from the Office of the Illinois Attorney General's Tobacco Enforcement Bureau that its VLN cigarettes will be listed in the Illinois Directory of Participating Manufacturers effective April 4, 2022.

22nd Century Group: Q4 Earnings Insights

22nd Century Group: Q4 Earnings Insights

22nd Century Group (NASDAQ:XXII) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

22nd Century Group Welcomes Dr. Robert Califf's Confirmation As FDA Commissioner

22nd Century Group, Inc. (NASDAQ: XXII) an agricultural biotechnology company focused on tobacco harm reduction, congratulated Dr.

22nd Century Group And KeyGene Achieve Breakthrough In Hemp/Cannabis GMO Research

22nd Century Group, Inc.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

Palantir Technologies

Las Vegas Sands

IDEXX Laboratories

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

302,699 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play